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Cystathionine γ-lyase is expressed 
in human atherosclerotic plaque 
microvessels and is involved in 
micro-angiogenesis
J. C. van den Born1, R. Mencke1, S. Conroy1, C. J. Zeebregts2, H. van Goor1 & J. L. Hillebrands1
Atherosclerotic plaques are classically divided into stable and vulnerable plaques. Vulnerable plaques 
are prone to rupture with a risk for infarction. High intraplaque microvessel density predisposes to 
plaque vulnerability. Hydrogen sulfide (H2S) is a proangiogenic gasotransmitter which is endogenously 
produced by cystathionine γ-lyase (CSE), and is believed to have vasculoprotective effects. However, 
due to its proangiogenic effects, H2S may result in pathological angiogenesis in atherosclerotic plaques, 
thereby increasing plaque vulnerability. The aim of this study was to determine CSE expression pattern 
in atherosclerotic plaques, and investigate whether CSE is involved in micro-angiogenesis in vitro. 
Endarterectomy plaques were studied for CSE expression, and the role of CSE in micro-angiogenesis 
was studied in vitro. CSE is expressed in plaques with similar levels in both stable and vulnerable 
plaques. CSE co-localized with von Willebrand Factor-positive microvessel endothelial cells and alpha-
smooth-muscle actin-positive SMCs. In vitro, inhibition of CSE in HMEC-1 reduced tube formation, cell 
viability/proliferation, and migration which was restored after culture in the presence of H2S donor 
GYY4137. CSE is expressed in intraplaque microvessels, and H2S is a stimulator of micro-angiogenesis  
in vitro. Due to this pro-angiogenic effect, high levels of CSE in atherosclerotic plaques may be a 
potential risk for plaque vulnerability.
Cardiovascular diseases are the predominant cause of death in developed countries1. The main cause is athero-
sclerosis, a chronic vascular disease characterized by plaque formation. Depending on the cellular and matrix 
composition, plaques can be classified as stable or unstable2. Stable plaques cause luminal narrowing but are less 
prone to rupture, whereas unstable/vulnerable plaques are prone to rupture, resulting in ischemic stroke and 
myocardial infarction. Intraplaque angiogenesis (i.e., high microvessel density) is associated with intraplaque 
hemorrhage and plaque vulnerability, resulting in symptomatology3,4.
Angiogenesis is stimulated by hydrogen sulfide (H2S), a gaseous signaling molecule5,6. H2S is recognized as 
the third gasotransmitter next to nitric oxide (NO) and carbon monoxide (CO)7. H2S is endogenously produced 
by three enzymes cystathionine γ -lyase (CSE), cystathionine β -synthase (CBS), and 3-mercaptopyruvate sul-
furtransferase (3MST). In vascular tissue, CSE is considered the major H2S synthesizing enzyme. H2S induces 
vasodilatation, reduces inflammation, inhibits platelet aggregation and scavenges reactive oxygen species8–11.
The proangiogenic effects of H2S have been demonstrated in experimental model systems in vivo as well as 
ex vivo. Administration of the CSE inhibitor D,L-propargylglycine (PPG) resulted in inhibition of angiogenesis 
in chorioallantoic membrane6. Moreover, VEGF-induced angiogenesis was absent in aortic ring explants from 
CSE-deficient mice indicating that angiogenesis is CSE-dependent in this model12.
Systemic administration of H2S donors is vasculoprotective in experimental models for cardiovascular dis-
ease13. Administration of sodium hydrosulfide (NaHS) reduced atherosclerotic plaque size in ApoE−/− mice14. 
Furthermore, CSE deficiency aggravated atherosclerotic plaque formation and smooth muscle cell proliferation, 
an effect which could be rescued by administration of NaHS15–17.
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In the early phase of plaque development (i.e. endothelial dysfunction and fatty streak formation) the CSE/H2S 
pathway is clearly vasculoprotective. However, during plaque progression, composition of the plaque becomes 
increasingly important in terms of vulnerability. Since H2S is a known pro-angiogenic molecule, we hypothesize 
that local intraplaque H2S production could aggravate plaque vulnerability by promoting intraplaque angiogen-
esis. To our best knowledge, no data exist about endogenous H2S production in human macrovasculature and 
atherosclerosis.
The aim of the present study is to determine CSE expression in atherosclerotic plaques, and the role of 
CSE-derived H2S in micro-angiogenesis. To investigate this, we studied human carotid endarterectomy plaques 
for CSE protein expression. Furthermore, the effect of inhibition of CSE expression and activity, and subsequent 
rescue by exogenous H2S, on HMEC-1 micro-angiogenesis, proliferation and migration was studied in vitro.
Results
Patient characteristics. Patient characteristics (n = 19) at time of carotid endarterectomy (CEA) are shown 
in Table 1. Most of the patients were male (79%). The mean age of all patients was 72.2 ± 8.1 yrs. According to the 
guidelines, 15 patients were overweight (BMI > 25 kg/m2), and 8 patients suffered from obesity (BMI > 30 kg/m2), 
with a mean BMI of 28.7 ± 3.5. Systolic blood pressure was 146 ± 14 mmHg, and diastolic blood pressure was 
72 ± 12 mmHg.
Atherosclerotic plaque characteristics. The carotid plaque specimens were divided into either vulner-
able or stable based on the criteria described in the Methods section. Criteria included the following parameters: 
fibrous cap thickness, CD68+ macrophage infiltration, density of intraplaque microvessels, and the presence of 
intraplaque hemorrhage. Figure 1 displays representative examples of a vulnerable and stable plaque. Vulnerable 
plaques were characterized by cholesterol cleft abundance, intraplaque hemorrhage, macrophage infiltration and 
intraplaque angiogenesis. To validate our plaque classification, plaques depicted in Fig. 1 were also classified 
according to the Oxford plaque classification18. According to this classification the overall stability of the vulnera-
ble plaque would be “unstable with ruptured cap” due to the presence of a thrombus. The fibrous cap in the stable 
plaque is > 200 μ m at the thinnest and therefore scored “stable” according the Oxford Plaque Classification19. Our 
classification and the Oxford Plaque Classification thus has similar outcome with respect to plaque stability. Out 
of 19 CEA plaques, 8 were classified as vulnerable. No significant differences were observed in patient character-
istics between patients with stable and vulnerable plaques (Table 1). However, 3 out of 4 plaques from asympto-
matic patients were classified as stable, suggesting that in our patient cohort asymptomatology is associated with 
plaque stability.
CSE is expressed in intraplaque microvessel endothelial cells. In all plaques (n = 19), lumen nar-
rowing, inflammatory cell infiltration, and microvessels were observed (Fig. 1). To determine intraplaque CSE 
protein expression levels, western blot analysis on both stable and vulnerable plaques was performed (Fig. 2A). 
No differences in CSE expression levels were observed between stable and vulnerable plaques. We also attempted 
to perform reproducible real time PCR analysis to determine intraplaque CSE mRNA expression levels. This was 
however not possible due to poor RNA quality with high A260/A280 ratio and low yields (data not shown), despite 
reproducible and reliable protein expression. To determine the localization of intraplaque CSE expression, immu-
nohistochemistry was performed. As shown in Fig. 2B and Fig. 3A–C, CSE protein was localized within micro-
vascular structures in CEA plaques. To confirm the endothelial phenotype of CSE-expressing cells, CSE/vWF 
immunohistochemical and immunofluorescence double labeling were performed. Double staining for CSE/vWF 
showed CSE expression in vWF+ endothelial cells (Fig. 3D–F,J) but also in cells of non-endothelial origin which 
Overall n = 19 Stable n = 11 Vulnerable n = 8 P-trend
Demographics
 Age (years) 72.2 ± 8.1 73.4 ± 8.5 71.2 ± 7.3 0.56
 Male gender 15 (79%) 9 (82%) 6 (75%) 0.72
 BMI (kg/m2) 28.7 ± 3.5 29.5 ± 3.0 27.6 ± 4.0 0.25
 Smoking* 8 (42%) 3 (27%) 5 (63%) 0.26
 Symptomatology 15 (79%) 8 (73%) 7 (88%) 0.44
 Symptoms - surgery interval (days)† 25 ± 14 23 ± 10 27 ± 18 0.64
Clinical parameters
 SBP (mmHg) 146 ± 14 145 ± 15 147 ± 12 0.86
 DBP (mmHg) 72 ± 12 75 ± 12 68 ± 10 0.18
 Serum creatinine (μ mol/L) 91 ± 17 88 ± 13 96 ± 22 0.36
Co-morbidity
 Diabetes mellitus 5 (26%) 2 (18%) 3 (38%) 0.25
 Hypertension 18 (95%) 11 (100%) 7 (88%) 0.39
 Hyperlipidemia 16 (84%) 10 (91%) 6 (75%) 0.35
Table 1.  Patient characteristics. Data are presented as mean ± SD or n (%). *Smoking is presented as current 
smokers including abstinence < 1 year. †Symptoms - surgery interval is presented as days from first symptoms 
until day of surgery (only in symptomatic patients).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:34608 | DOI: 10.1038/srep34608
appeared to be α SMA+ smooth muscle cells (Fig. 3G–K). Conjugate controls, as well as IgG1 isotype controls, 
were consistently negative (Suppl. Fig. 1).
CSE siRNA knockdown in HMEC-1 significantly reduces CSE mRNA expression. To study the 
effect of CSE on functional characteristics of HMEC-1 cells in vitro (i.e. tube formation, cell viability/prolifera-
tion, migration), CSE siRNA knockdown was established using two different CSE-specific siRNA’s. PCR analysis 
confirmed down-regulation of CSE mRNA in HMEC-1 cells 24, 48, and 72 hours after CSE mRNA knockdown. 
Both siRNA 1 (s3710) and siRNA 2 (s3711) resulted in a significant down-regulation of CSE mRNA expression 
(P < 0.001; Fig. 4A). Western blot analysis performed after 48 hours confirmed CSE knockdown, and revealed a 
decreased CSE protein expression with siRNA 1 (n.s.) and siRNA 2 (P < 0.05; Fig. 4B). In order to achieve more 
pronounced knockdown, double CSE knockdown was performed. To determine whether the potential effects 
of CSE knockdown resulted from reduced H2S production, exogenous H2S was added to the cultures by adding 
slow release H2S compound GYY4137. Double CSE knockdown resulted in 88% decreased CSE mRNA expres-
sion, which was unaffected by GYY4137 (Fig. 4C). At the protein level, double CSE knockdown resulted in 45% 
Figure 1. Plaque morphology. Representative photomicrographs of a vulnerable plaque (A,C,E,G) and a 
stable plaque (B,D,F,H). Images show narrowed lumen (PAS staining) (A,B) and cholesterol clefts. Fibrous 
cap and connective tissue was visualized with MSB staining (blue) (C,D). Fibrin, indicating an intraplaque 
hemorrhage, is stained red. Inflammatory cells, identified by positive CD68 staining are shown in panels (E,F). 
Intraplaque microvessels were characterized by positive CD34 staining (G,H). Scalebar 2 mm in overview 
photomicrographs and 200 μ m in detailed pictures.
www.nature.com/scientificreports/
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decreased CSE expression, which was not significantly affected by GYY4137 (Fig. 4D). CSE knockdown did not 
alter CBS or 3MST mRNA expression levels as evidenced by real-time PCR analysis (Suppl. Fig. 2).
Inhibition of CSE decreases tube formation. Cultured HMEC-1 cells were positive for vWF as well 
as CSE. Conjugate controls were consistently negative (Fig. 5A). HMEC-1 started to form tubes and capillary 
networks one hour after seeding, with maximal tube formation observed after 8 hrs. PPG was used to inhibit 
CSE activity. PPG dose-dependently inhibited tube formation up to 34% (Fig. 5B,D). PPG did not influence CSE 
mRNA expression (Suppl. Fig. 3). Single (one siRNA) and double (two siRNAs) CSE mRNA knockdown resulted 
in reduced tube formation (P < 0.001; Fig. 5C,E), which was restored to 99% of control after culture in the pres-
ence of slow release H2S donor GYY4137. GYY4137 without CSE knockdown stimulated tube formation with 
16% (P < 0.05; Fig. 5F).
Reduced CSE expression decreases cell viability. We next analyzed whether CSE knockdown also 
attenuated cellular processes related to angiogenesis, i.e. cell viability/proliferation and migration. Double (two 
siRNAs) CSE mRNA knockdown resulted in decreased cellular activity or viability compared to the scrambled 
siRNA control, as evidenced by lower absorbance in the MTT assay. Addition of GYY4137 significantly attenu-
ated this effect. Administration of GYY4137 alone increased cell viability in HMEC-1 cells, compared to negative 
control (scrambled siRNA) (two-way-ANOVA, p < 0.001, Fig. 6A). These data indicate that CSE-derived endog-
enous H2S increases cell viability. The effect of CSE knockdown can be overcome by exogenous H2S.
CSE knockdown inhibits HMEC-1 migration. Using a wound healing scratch assay double CSE mRNA 
knockdown decreased HMEC-1 migration when compared to the scrambled siRNA control. After 24 hours, 53% 
of the scratch was closed in the scrambled siRNA control, whereas after double CSE mRNA knockdown this was 
significantly lower (41%, two-way-ANOVA, p < 0.05). Addition of GYY4137 was able to diminish the effects of 
CSE knockdown (52% closure). GYY4137 alone resulted in increased cell migration (65% scratch closure) when 
compared with the scrambled siRNA control (two-way-ANOVA, p < 0.05, Fig. 6B). Similar to HMEC-1 tube 
formation and viability, these data indicate that CSE-derived endogenous H2S increases cell migration.
CSE knockdown results in reduced expression of VEGFR2. To study a possible pathway of 
pro-angiogenic effects of H2S, VEGF-A and VEGFR2 expression levels were analyzed in HMEC-1 cells. PCR anal-
ysis revealed significantly decreased VEGFR2 mRNA expression levels after CSE siRNA knockdown (Fig. 7A). 
No differences were observed for VEGF-A mRNA expression levels (Fig. 7B). Supernatant VEGF-A protein levels 
were below detection limit (Fig. 7C).
Figure 2. Carotid endarterectomy plaques express cystathionine γ-lyase (CSE). Representative western blot 
showing (variable) CSE protein expression and its quantitative analysis (n = 19 plaques) (A). No differences 
were observed between stable or vulnerable plaques. Photomicrograph of a CEA plaque showing positive 
immunohistochemical staining for CSE in microvascular structures (closed arrowheads), and elongated cells 
(open arrowheads) (B).
www.nature.com/scientificreports/
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Figure 3. CSE is present in microvascular endothelial cells and αSMA+ cells. Representative 
photomicrographs of a plaque with CSE expression in intraplaque microvessels (A–C). Immunohistochemical 
double staining for CSE and vWF immunohistochemical staining, (D) showing double positivity in 
microvascular endothelial cells (E,F). CSE protein is visualized with AEC (red) and vWF with FastBlue (blue). 
Immunohistochemical double staining for CSE and α SMA (G), showing double positivity in intraplaque 
smooth muscle cells (H), but only CSE positivity in intraplaque microvessels (I). CSE protein is visualized with 
FastRed (red) and α SMA with DAB (brown). Scalebar: 2 mm (A,D,G); 100 μ m (B,E,H); and 50 μ m (C,F,I). 
Immunofluorescence double staining for CSE and vWF, showing co-localization in microvascular endothelial 
cells (closed arrowheads), 400× magnification, scalebar: 20 μ m (J). Immunofluorescence double staining for 
CSE and α SMA, showing co-localization of CSE and α SMA in myofibroblast-like cells (open arrowheads), 
400× magnification, scalebar: 20 μm (K).
www.nature.com/scientificreports/
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Discussion
Major findings of this study are: 1) the detection of high levels of CSE in intraplaque microvessels in human CEA 
atherosclerotic plaques, 2) the stimulatory effect of CSE on angiogenesis of microvascular endothelium in vitro, 
and 3) CSE knockdown results in decreased expression levels of VEGFR2 mRNA after CSE knockdown. All 
together, these findings support a role for intraplaque H2S production as a risk factor for increased microvascular 
density, and thereby plaque vulnerability.
Unfortunately, we were not able to analyze intraplaque gene expression for CSE and the other H2S producing 
enzymes at the mRNA expression level. Due to large acellular areas of advanced plaques and degradation of RNA, 
the yield was very low and the mRNA quality rather poor. This is a technical issue, which has been described 
before20.
Figure 4. Confirmation of CSE knockdown with CSE siRNAs. HMEC-1 transfection with siRNA 1 
(s3710) resulted in a dowregulation of CSE mRNA of 83%, 80% and 84%, and siRNA 2 (s3711) resulted in a 
dowregulation of 75%, 71% and 69% after 24, 48 and 72 hours respectively (A), n = 3, in which each replicate was 
performed in triplicate. Western blot analysis for CSE in HMEC-1 cells, showing a reduction of 26%  
(siRNA 1) and 51% (siRNA 2) of CSE protein expression (B) n = 3. qRT-PCR analysis for CSE in cultured 
HMEC-1 cells, 48 hours after transfection with two CSE siRNAs and addition of GYY4137, showing 88%  
(2× CSE siRNA) and 89% (2× CSE siRNA + GYY) knockdown of CSE mRNA expression compared to negative 
control. GYY4137 did not affect CSE mRNA expression (C), n = 3, in which each replicate was performed in 
triplicate. Western blot analysis for CSE in HMEC-1 cells, 48 hours after transfection with double CSE siRNA 
knockdown and addition of GYY4137, showing 45% (2× CSE siRNA) and 29% (2× CSE siRNA + GYY) 
knockdown of CSE protein expression compared to negative control (scrambled siRNA). GYY4137 did not 
affect CSE protein expression significantly (D) n = 3. Data are expressed as mean ± SEM of three independent 
siRNA transfection experiments. *P < 0.05, **P < 0.01, ***P < 0.00 vs. control. Data were analyzed using one-way 
ANOVA. Normality was tested using the Kolmogorov–Smirnov test. Bonferroni post-hoc analysis was applied to 
correct for multiple comparisons.
www.nature.com/scientificreports/
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The tube formation assay with HMEC-1 cells was used as an in vitro model for micro-angiogenesis. Inhibition 
of CSE resulted in decreased tube formation, an effect that was rescued after adding GYY4137, a H2S donor. 
Similar results were obtained for HMEC-1 cell viability and migration. The observation that the functional phe-
notypes of CSE-deficient HMEC-1 cells can be rescued by exogenous H2S indicates that these CSE-dependent 
processes are H2S-mediated. The anti-angiogenic effects of CSE knockdown are possibly mediated via the 
VEGFR2 pathway. H2S can directly target VEGFR221 but also indirectly as explained in more detail below. Our 
data indicate that human microvascular endothelial cell-mediated angiogenesis is, at least in part, regulated by 
H2S. Our results are in line with the previous reported pro-angiogenic actions of H2S5,6,12. However, here we 
describe pro-angiogenic effects of H2S on human microvascular endothelial cells in vitro. Intraplaque microves-
sels are composed of microvascular endothelial cells which prompted us to use human microvascular HMEC-1 
cells; we believe this in vitro assay would be the best approximation of the in vivo situation. Since our in vitro 
data are in line with previous reports5,6,12, we assume that the underlying molecular mechanisms might also be 
Figure 5. Inhibition of CSE in HMEC-1 cells reduces tube formation. Immunohistochemical staining  
of HMEC-1 cells for vWF and CSE. Conjugate controls were consistently negative. Scalebar: 100 μ m  
(A) Representative photomicrographs showing tube formation assay with HMEC-1 cells in the presence of 
increasing concentrations (0–10 mM) of the irreversible CSE inhibitor PPG (B) transfected with scrambled 
siRNA (negative control), CSE siRNA 1 (s3710) and CSE siRNA 2 (s3711) and/or with slow release H2S donor 
GYY4137 (C) PPG dose-dependently decreases tube formation by 6%, 25%, 29%, and 34% with 1 mM, 2 mM, 
5 mM, and 10 mM PPG respectively (D) CSE knockdown with siRNA 1 and siRNA 2 resulted in decreased tube 
formation of respectively 26% and 33% (E) GYY4137 significantly increased tube formation by 16%, double 
CSE knockdown inhibited tube formation with 27%, which was recovered by GYY4136 to 99% of control 
(F). For all tube formation experiments: n = 3, in which each replicate was performed in triplicate. Data are 
expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control ###P < 0.001 vs. 2× CSE siRNA. Data 
were analyzed using one-way ANOVA. Normality was tested using the Kolmogorov–Smirnov test. Bonferroni 
post-hoc analysis was applied to correct for multiple comparisons.
www.nature.com/scientificreports/
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Figure 6. Inhibition of CSE in HMEC-1 cell viability and migration. In the MTT assay, double CSE mRNA 
knockdown resulted in inhibition cell viability of HMEC-1, compared to negative control (scrambled siRNA), 
and addition of 300 μ mol/L GYY4137 was able to temporarily diminish this effect. Addition of GYY4137 
alone resulted in induced mitochondrial activity compared to negative control (A). The MTT assay was 
repeated three times. For the scratch assay, representative pictures for each condition are shown to visualize 
scratch-closure over time. After 24 hours, 53% of the scratch was closed in the negative control conditions. 
Addition of GYY4137 significantly increased scratch closure at 24 hours, up to 65%. Double CSE knockdown 
decreased migration of HMEC, with a scratch closure of 41%, an effect which was reversed by addition of GYY 
with a scratch closure of 52% after 24 hours (B). Each condition in the scratch assay was repeated six times. 
Data are expressed as mean ± SEM. *P < 0.05, ***P < 0.001 vs. scr. siRNA; #P < 0.05, ###P < 0.001 vs. 2× CSE 
siRNA + GYY. Data were analyzed using two-way ANOVA. Normality was tested using the Kolmogorov–
Smirnov test. Bonferroni post-hoc analysis was applied to correct for multiple comparisons.
www.nature.com/scientificreports/
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similar. Although not determined by us in HMEC-1 cells, we propose that also in these cells H2S might promote 
angiogenesis involving pathways such as PI3K/AKT and MAPK pathways, as well as ATP-sensitive K-channels6. 
Recently, microRNA miR-640 was identified as a key regulator of the proangiogenic effects of H2S22. In response 
to H2S, expression of miR-640 was reduced in HUVECs and HMEC-1 cells through the VEGFR2-mTOR pathway 
resulting in increased HIF1A expression. HIF1A is a known regulator of angiogenic growth factors that promote 
angiogenesis eventually.
Composition of carotid atherosclerotic plaques, and its association with plaque rupture and cardiovascular 
events has been reported before23. Based on previous research, plaque neovascularization is associated with a 
more rupture-prone plaque phenotype and is increased in ruptured atherosclerotic plaques24. The predominant 
trigger for the development of plaque neovascularization are hypoxic conditions in the microenvironment of the 
necrotic core25. The intraplaque microvessels are presumed to originate from the adventitial vasa vasorum that 
infiltrate the damaged medial wall26. Here we clearly demonstrated CSE expression in intraplaque microvessels, 
which supports the concept that intraplaque produced H2S may further promote angiogenesis. Based on our data 
we cannot draw firm conclusions as to whether intraplaque hypoxia increases microvascular CSE expression. 
However, there is ample evidence for a role of increased demand of H2S in ischemic conditions. For example, 
inhibition of CSE in rats subjected to bilateral renal ischemia and reperfusion worsened renal function, indicating 
that the endogenous production of H2S is crucial in the recovery period after ischemia27. In mice subjected to 
ischemia and reperfusion, renal H2S production and plasma concentrations of H2S were increased after 24 hours, 
suggesting a reparative role for H2S after ischemia and reperfusion28. In line with this, we previously showed that 
in CSE knock out mice mortality is significantly higher when compared to wild type mice after subjection to 
bilateral ischemia and reperfusion11.
Also in more direct cell-based assays it was reported that hypoxia modulates CSE expression trough (post-)
transcriptional regulation which may result in increased CSE protein levels29. We therefore propose that 
intraplaque hypoxia is likely to be responsible for preserved or even increased CSE expression in intraplaque 
microvessels.
Inhibiting microvessel formation in atherosclerotic plaques may be a strategy to reduce the risk for plaque 
rupture. Since angiogenesis is induced by CSE-derived H2S, this pathway seems a good candidate for targeted 
therapeutic inhibition. However, the therapeutic potential of systemic CSE inhibition is hampered by the fact 
that CSE and H2S have systemic anti-atherogenic effects, including the scavenging of reactive oxygen species, 
inhibition of vascular smooth muscle cell proliferation, and reduction of inflammation15,30. Overexpression of 
CSE31, exogenous administration of NaHS (a fast H2S donor),14 or GYY4137 (a slow release H2S donors)32 showed 
Figure 7. VEGFR2 and VEGF-A expression during CSE knockdown. qRT-PCR analysis for VEGFR2 in 
cultured HMEC-1 cells, showing 25% (CSE siRNA 1) and 10% (CSE siRNA 2) decreased VEGFR2 mRNA 
expression (A) n = 3, in which each replicate was performed in triplicate. qRT-PCR analysis revealed no 
differences in VEGF-A mRNA expression levels in HMEC-1 cells after transfection with different siRNAs 
(B) n = 3, in which each replicate was performed in triplicate. ELISA revealed undetectable low VEGF-A 
concentrations in supernatant of transfected cells, and showed no differences in VEGF-A concentration in 
HMEC-1 cells after transfection with different siRNAs (C), n = 3, in which each replicate was performed in 
duplicate. Data were analyzed using Kruskal Wallis test. Normality was tested using the Kolmogorov–Smirnov 
test. Dunns post-hoc analysis was applied to correct for multiple comparisons.
www.nature.com/scientificreports/
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reduction of atherosclerotic plaque size in ApoE−/− mice. In line with this, atherosclerosis is accelerated in CSE 
deficient mice16. CSE deficiency is also accompanied by a lower vessel density in an ischaemic limb model in mice, 
an effect which was reduced with H2S donor diallyl trisulfide33. Based on these published data and our data pre-
sented here, local intraplaque CSE inhibition with preserved systemic CSE activity is required. It has been shown 
that CSE and VEGF both act via a common pathway in angiogenesis as VEGF-stimulated growth of microvessels 
in mouse aortic rings is dependent on the presence of active CSE12. In addition, it has been shown that H2S could 
directly activate VEGFR221 as already eluded to above. Local treatment with soluble vascular endothelial growth 
factor receptor-1 (sFlt-1) as a VEGF inhibitor was shown to be a promising treatment modality against plaque 
development and progression in rabbits34. However, systemic VEGF inhibition using the selective VEGFR2 
blocker PTK787 in ApoE−/− mice augmented atherosclerotic plaque development compared to placebo treat-
ment35. These data underscore the importance of local vs. systemic inhibition of angiogenesis and should be 
taken into account when considering CSE as a potential target for intervention. As miR-640 is identified as a key 
regulator of the proangiogenic effects of H2S22 also locally (intraplaque) increased expression of miR-640 (or miRs 
with similar effects) might be considered to reduce H2S-mediated angiogenesis.
Our hypothesis contrasts earlier described atheroprotective effects of the CSE/H2S pathway in atherogenesis. 
Based on our data we propose that the CSE/H2S pathway might be protective in the early phase of plaque forma-
tion by e.g. attenuating endothelial dysfunction and reducing inflammation. However, during plaque progression 
CSE/H2S might actually promote plaque vulnerability due to its pro-angiogenic effects. One should be aware of 
this potential risk when considering H2S as treatment modality for atherosclerosis.
In conclusion, we here demonstrate microvessel-associated CSE expression in human atherosclerosis. 
Although microvessel formation might be beneficial for cells to survive hypoxia in the expanding plaque, it may 
actually increase plaque vulnerability. High levels of CSE in atherosclerotic plaques may be a potential risk for 
plaque vulnerability through the local production of H2S.
Methods
Carotid endarterectomy specimens. Atherosclerotic plaques were obtained from patients undergoing 
carotid endarterectomy (CEA) for atherosclerotic carotid disease. Patients were referred to as symptomatic when 
suffering from stroke, transient ischemic attack or amaurosis fugax. CEA was performed when internal carotid 
artery stenosis was > 70%. CEA specimens were divided into different parts that were either snap frozen at − 80 °C 
or fixed in formaldehyde and paraffin-embedded. The study was performed conform to the principles of the 
Declaration of Helsinki and approved by the Institutional Review Board. All patients provided informed consent.
Immunohistochemistry and immunofluorescence. Histochemical stainings were performed on par-
affin sections of all plaques to assess general morphology (PAS staining), intraplaque hemorrhage and fibrous cap 
thickness (Martius, Scarlet and Blue; MSB staining).
For immunostaining, frozen sections were fixed in 100% acetone, and cultured HMEC-1 cells were fixed in 
90% acetone/10% dH2O at − 20 °C for 10 minutes. Sections or cells were subsequently stained for human CSE 
(mouse IgG1 κ monoclonal, Abnova, clone S51), human vWF (rabbit polyclonal, Dako, ref: A0082), human 
α SMA (mouse IgG2a κ monoclonal, Dako, ref: M0851), human CD34 (mouse IgG1 κ monoclonal, Dako, clone 
QBEnd-10, code number M7165), or human CD68 (mouse IgG3 κ monoclonal, Dako, clone KP-1). Following 
incubation with primary antibodies (1 hr, room temperature), sections/cells were incubated with HRP-conjugated 
rabbit-anti-mouse IgG (CSE and α SMA) or goat-anti-rabbit IgG (vWF) polyclonal antibodies (Dako). 
3-amino-9-ethylcarbazole (AEC) or 3,3′ -diaminobenzidine (DAB) was used as chromogen, and nuclei were 
counterstained using hematoxylin.
For CSE/vWF immunohistochemical double staining, frozen sections of plaques were fixed in 100% acetone, 
and incubated with mouse IgG1 anti-human-CSE for 1 hour at room temperature. Sections were subsequently 
incubated with goat-anti-mouse IgG1 biotin labeled, and streptavidin-HRP. HRP-activity was visualized using 
AEC. Sections were then incubated with the rabbit anti-human-vWF for another hour, followed by incubation of 
goat-anti-rabbit-alkaline phosphatase and stained using FastBlue (Life Technologies, Bleiswijk, The Netherlands). 
For α SMA/CSE immunohistochemical double staining, frozen sections of plaques were fixed in 100% ace-
tone, and incubated with mouse IgG2a anti-human-α SMA for 1 hour, followed by goat-anti-mouse IgG2a-HRP. 
HRP-activity was visualized using DAB. After that, sections were incubated with the second primary antibody, 
mouse IgG1 anti-human-CSE for 1 hour, followed by incubated with goat-anti-mouse IgG1 biotin labeled, and 
streptavidin-alkaline phosphatase and stained using FastRed. Nuclei were counterstained using hematoxylin.
Immunofluorescent double labeling for CSE and vWF or CSE and α SMA was performed as described above using 
goat-anti-mouse-IgG1-TRITC (for CSE) and goat-anti-rabbit-FITC (for vWF) or goat-anti-mouse-IgG2a-FITC 
(for α SMA) (SouthernBiotech) as secondary antibodies. Nuclei were counterstained with DAPI. Primary antibody 
was replaced by PBS in negative controls.
Plaque vulnerability score. All 19 carotid atherosclerotic plaque specimens were assessed for vulnerability. 
For plaque vulnerability score, the following criteria were taken into account: microvessel density, thickness of the 
fibrous cap, CD68+ macrophage infiltration and the presence of intraplaque hemorrhage. Intraplaque microvessel 
density was determined in two hotspots. A hotspot is defined as one field of view at 200 × magnification. CD34+ 
microvessels were manually counted in two hotspots, and mean number of CD34+ microvessels per mm2 was 
calculated. Microvessel density resulted in the following vulnerability score; (0) less then 10 microvessel per mm2, 
(1) between 10 and 20 microvessels per mm2, and (2) more then 20 microvessels per mm2. Fibrous cap thick-
ness was based upon the MSB staining. The visually thinnest part of the fibrous cap was measured, and scored 
according to the Critical Cap Thickness criteria;19 (0) the thinnest part of the fibrous cap was > 200 μ m, and (1) 
the thinnest part of the fibrous cap was < 200 μ m. Inflammation in the plaque was assessed by measurement of 
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CD68+ macrophages. CD68 stained sections were scanned using the NanoZoomer 2.0HT Digital slide scanner 
(Hamamatsu, Japan) and analyzed for positive pixel area (CD68) using the Aperio Positive Pixel Analysis v9.1 
algorithm. CD68 staining resulted in the following vulnerability score; (0) less then 2% CD68 positive pixel area, 
and (1) more then 2% CD68 positive pixel area. Finally, intraplaque hemorrhage was determined, based on the 
MSB staining and resulted in the following vulnerability score; (0) no detectable intraplaque hemorrhage, and 
(2) detectable intraplaque hemorrhage. The total sum of the scores was calculated to a total vulnerability score. 
A score lower then 4 was defined as stable plaque, and a score of 4 or higher was defined as vulnerable plaque.
HMEC-1 cell culture. Human dermal microvascular endothelial cells (HMEC-1) were kindly provided by 
Dr. E.W. Ades (CDC, Atlanta, USA)36 via Prof. G. Molema and the UMCG Endothelial Cell Facility. Cells were 
cultured in M-199 medium (Lonza) supplemented with 10% (v/v) FCS (HyClone), 10% (v/v) human serum 
(Lonza), 2 mM L-glutamine (Lonza) and 100 U/ml penicillin and 100 μ g/ml streptomycin (Lonza). Cells were 
expanded in T75 flasks (Corning) at 37 °C and 5% CO2 in a humidified atmosphere. For immunophenotyping, 
cells were cultured on coverslips. Tube formation assays were performed as described below.
CSE knockdown in HMEC-1. Endogenous H2S production by CSE was downregulated by transfection 
with small interfering RNA (siRNA). Two different CSE siRNAs were used for this purpose (Silencer® Select 
siRNA, s3710 and s3711, Life Technologies). Scrambled siRNA was used as a negative control (Silencer® Select 
Negative Control No. 1 siRNA 4390843). Experiments were performed following the user’s guide. Briefly, 200 μl 
opti-MEM reduced medium (Gibco®, Life Technologies) per well was added in a 12-well plate. To each well 
4.8 μ l siRNA (2.5 μ mol/L) was added, as well as 2 μ l Lipofectamine RNAiMAX (Life Technologies). Next, 1 ml 
of cell-suspension was added per well, resulting in a final concentration of 10 nmol/L siRNA. After 24, 48, and 
72 hours, cells were harvested for PCR analysis and western blot analysis. In order to accomplish more pro-
nounced knockdown, double CSE knockdown with the 2 CSE siRNAs was performed. For double CSE knock-
down experiments 200 μ l opti-MEM reduced medium per well was added in a 12-well plate. To each well either 
4.8 μ l scrambled siRNA (2.5 μ mol/L) and 2 μ l Lipofectamine RNAiMAX was added per well, or 4.8 μ l CSE siRNA 
1 and 4.8 μ l CSE siRNA 2 and 4 μ l Lipofectamine RNAiMAX was added per well. Next, 1 ml of cell-suspension was 
added per well, resulting in a final concentration of 10 nmol/L per siRNA. 12 hours after transfection, GYY4137 
(30 mM) was administered to a final concentration of 300 μ M GYY4137.
HMEC-1 tube formation. A Matrigel tube formation assay was performed using HMEC-1 cells to study 
angiogenic capacity of microvascular endothelial cells. Ten μ l growth factor-reduced Matrigel (BD Biosciences) 
was allowed to polymerize at 37 °C for 30 minutes in Angiogenesis μ -slides (Ibidi GmbH). HMEC-1 cells 
were plated on the Matrigel surface (5000 cells/well in 50 μ l serum-free medium). To inhibit CSE activity, 
DL-propargylglycine (PPG, Sigma-Aldrich) was used. Tube formation was performed in presence of CSE inhib-
itor PPG using various concentrations (0, 1, 2, 5 and 10 mmol/L) in order to inhibit CSE activity. To inhibit CSE 
mRNA expression two different siRNAs (single or in combination) were used as described above and tube for-
mation was analyzed 40 hours after transfection. Slow release H2S compound GYY4137 (kindly provided by M. 
Whitemann, Exeter, UK) was used as an H2S donor in a concentration of 300 μ mol/L37. After 8 hours, images were 
taken from 5 selected areas per well in a standardized way. The total number of branching points in the 5 images 
was determined using Aperio Imagescope software (Aperio Technologies). The tube formation assay was repeated 
three times, in which each replicate was performed in triplicate.
MTT cell viability assay. To examine cell viability and mitochondrial activity of HMEC-1, a 3-(4,5-dim
ethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) assay was used according to the manufacturer’s 
instruction. In short, HMEC-1 were transfected with siRNA and seeded into 96-well plates (2,500 cells per well). 
MTT reagent (10 μ l) was added after one hour (t = 0), after 24 hours (t = 1), 48 hours (t = 2) or 72 hours (t = 3). 
Four hours after MTT administration, formazan crystals were formed, 100 μ l isopropanol with 0.04 N HCl was 
added and thoroughly mixed to solubilize formazan. Directly after solubilization, the absorbance was measured 
at 570 nm and a reference wavelength of 630 nm (Varioskan, Thermo Scientific). The MTT assay was repeated 
three times.
HMEC-1 scratch assay. Migration activity of HMEC-1 cells was studied using the scratch assay. Cells were 
seeded in 24-well plates to confluence. 24 hours after transfection with siRNAs, a scratch was made with a pipette 
tip of a 200 μ l pipette. The medium was directly changed into serum-free medium and photomicrographs were 
taken (t = 0). Pictures were taken at 4 hours (t = 1), 8 hours (t = 2), and 24 hours (t = 3). Migration potential was 
expressed as percentage of scratch closure. Each condition in the scratch assay was repeated six times.
Western blot analysis. Protein was isolated from CEA cryosections (30 × 10 μ m) as well as from cul-
tured HMEC-1 cells using RIPA Buffer supplemented with 1% Halt Phosphatase inhibitor cocktail and 1% Halt 
Protease inhibitor cocktail, 0.1 mmol/L phenylmethylsulfonyl fluoride (PMSF) and 20 μ g/ml trypsin inhibitor. 
Total protein content of the lysates was determined with the pyrogallol red method as previously described38. 
Briefly, 5 μ l of sample was added in a 96-well plate (Corning), 300 μ l pyrogallol red-molybdate complex was then 
added. After 10 minutes absorbance was measured at 600 nm (Varioskan, Thermo Scientific) and protein con-
centration was calculated against a calibration curve. Equal amounts of protein were boiled and electropho-
retically separated in 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Aspecific binding of 
antibodies was blocked using 5% non-fat milk powder in Tris-buffered saline-0.1% Tween-20 (TBST) for 1 hour. 
Membranes were incubated with primary antibody overnight at 4 °C (for CSE; 1:500, mouse monoclonal IgG1κ, 
Abnova). β -actin (1:1000, mouse monoclonal IgG1, Santa Cruz Biotechnology) served as housekeeping pro-
tein. Horseradish peroxidase-labeled antibody was used as a secondary antibody. All antibody incubations were 
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followed by short washing with TBST. Immunoreactions were visualized by ECL Western Blotting Substrate 
(Thermo scientific, Waltham, MA, USA) and images were taken with the Bio-Rad-ChemiDoc MP system and 
quantified using ImageJ software.
Real-time PCR analysis. RNA was isolated from cultured HMEC-1 cells using TRIzol Reagent (Invitrogen). 
1 ug RNA was converted to cDNA using SuperScript II reverse transcriptase and random hexamere primers 
(Life Technologies). CSE (assay Hs00542284_m1), CBS (assay Hs00163925_m1), 3MST (assay Hs00560401_m1), 
VEGF-A (assay Hs00900055_m1) and VEGFR2 (assay Hs00911700_m1) mRNA expression was measured with 
a Taqman Gene expression assay (Applied Biosystems). For normalization, TATA box binding protein (TBP) 
was included as housekeeping gene using the following primers (FW: GCCCGAAACGCCGAATAT; REV: 
CCGTGGTTCGTGGCTCTCT) and probe (ATCCCAAGCGGTTTGCTGCGG) (Eurogentec). Reactions were 
performed on an ABI7900HT thermal cycler (Applied Biosystems). The comparative Ct method (2−ΔCt method) 
was used to calculate relative gene expression.
ELISA. Human VEGF-A was measured in supernatant of cultured HMEC-1 48 hours after transfection with 
different siRNAs (Quantikine ELISA Kit, Catalog# DVE00; R&D Systems). Analysis was performed according 
to the user’s guide. In short; 50 μ l Assay Diluent and the standards, blanks and samples (200 μ l) were added to 
each well. After 2 hours incubation, wells were washed three times followed by addition of 200 μ l Conjugate and 
incubation for 2 hours. After 3 times washing, 200 μ l of Substrate Solution was added and incubated at room tem-
perature in the dark. After 20 minutes, 50 μ l Stop Solution was added per well and within 30 minutes absorbance 
was measured at 450 nm (Varioskan, Thermo Scientific). VEGF-A concentration was then calculated by using the 
calibration curve.
Statistical analysis. All data were analyzed with GraphPad PRISM 5.0 (GraphPad, San Diego, CA, USA). 
Data were analyzed using one-way ANOVA or Kruskal Wallis test where appropriate. Normality was tested using 
the Kolmogorov–Smirnov test. Bonferroni or Dunns post-hoc analysis was applied to correct for multiple com-
parisons. Data are shown as mean ± SEM (Standard Error of the Mean). Differences were considered statistically 
significant when P < 0.05.
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